January 30, 2026 · Form 4 insider transaction
Daws D. Ryan bought 220,000 shares of enGene Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.